Opinion|Videos|January 9, 2024
Breakthrough Agents Reshaping RRMM Treatment Landscape
Noa Biran, MD, reviews approved bispecific T-cell engagers and how they redefine multiple myeloma treatment, yielding high response rates in refractory cases, but their use necessitates careful evaluation in later therapy lines.
Advertisement
Episodes in this series
Advertisement
Related to this article
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
3
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
4
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
5